RxDoctor Payments Data

Nikhil Sikand, MD

Advanced Heart Failure and Transplant Cardiology · New Haven, CTNPI 1558707844

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (52.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 10 manufacturers reported payments, led by Medtronic at 52.5% of the total.

$28,560in general payments, 2019–2025

Across 32 payments — averaging $892.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Bayer$10K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Vertex$492
  • Abbott$186
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$104
  • plus $123 from 4 others

What the payments were for

  • Consulting fees$10,76838%
  • Grants$15,00053%
  • Travel & lodging$1,6756%
  • Food & beverage$1,1034%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Connecticutto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$51,971
Medicare patients
288
Services billed
598

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CamzyosMavacamten16$129,752
EntrestoSacubitril/Valsartan60$47,355
FarxigaDapagliflozin Propanediol58$46,327
JardianceEmpagliflozin34$21,509
XareltoRivaroxaban16$9,773
Metoprolol Succinate57$545
Bumetanide25$305
Furosemide70$252
Spironolactone57$215
Atorvastatin Calcium19$193
Rosuvastatin Calcium26$172
Losartan Potassium42$162
Carvedilol29$133
Amlodipine Besylate25$31

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$3,042$129,75216 claims
NovartisEntresto$23$47,35560 claims
Boehringer IngelheimJardiance$14$21,50934 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Connecticuton file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →